New ALS treatment shows promise in early safety trial
NCT ID NCT02039401
First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 28 times
Summary
This early-stage study tested the safety of a new drug called VM202 in 18 people with amyotrophic lateral sclerosis (ALS). Participants received injections into their muscles to see if the treatment was safe and tolerable. The main goal was to track any side effects over 9 months, with a secondary focus on changes in muscle function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.